Document Detail


Use of nifedipine in hypertension and Raynaud's phenomenon.
MedLine Citation:
PMID:  2076403     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The reduction of transmembranous calcium influx into vascular smooth muscle cells by calcium antagonists leads to a reduction of tension development and vascular tone. Nifedipine reduces forearm vascular resistance dose-dependently when infused into the brachial artery in patients with essential hypertension, attesting to its potent arterial vasodilator effects. This effect can be successfully utilized for the treatment of essential hypertension, where nifedipine acts by reducing increased peripheral vascular resistance, thereby normalizing the main hemodynamic derangement of hypertensive patients. In contrast to other direct-acting vasodilators, the antihypertensive effect is not accompanied by sympathetic reflex activation or volume retention, making it feasible to use nifedipine as monotherapy for hypertensive patients. Although the pathophysiologic disturbances leading to vasospasm are not clear, blockade of slow calcium channels is also effective for the treatment of Raynaud's phenomenon, reducing attack frequency, digital pain, and functional disability in many patients, particularly those with primary Raynaud's phenomenon.
Authors:
W Kiowski; P Erne; F R Bühler
Related Documents :
3712523 - Experimental investigations on the antidotal treatment of nifedipine overdosage.
2372653 - Cardiovascular responses to verapamil and nifedipine in hypoventilated and hyperventila...
14559383 - Effects of 5 years of hormonal replacement therapy on menopausal symptoms and blood pre...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Review    
Journal Detail:
Title:  Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy     Volume:  4 Suppl 5     ISSN:  0920-3206     ISO Abbreviation:  Cardiovasc Drugs Ther     Publication Date:  1990 Aug 
Date Detail:
Created Date:  1991-04-24     Completed Date:  1991-04-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8712220     Medline TA:  Cardiovasc Drugs Ther     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  935-40     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine, Kantonsspital Basel, Switzerland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Female
Humans
Hypertension / drug therapy*
Male
Middle Aged
Nifedipine / therapeutic use*
Raynaud Disease / drug therapy*
Chemical
Reg. No./Substance:
21829-25-4/Nifedipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rationale for treatment of silent myocardial ischemia: focus on nifedipine.
Next Document:  Long-term therapy with slow-release nifedipine in essential hypertension.